ATE432987T1 - Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums - Google Patents

Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums

Info

Publication number
ATE432987T1
ATE432987T1 AT07001711T AT07001711T ATE432987T1 AT E432987 T1 ATE432987 T1 AT E432987T1 AT 07001711 T AT07001711 T AT 07001711T AT 07001711 T AT07001711 T AT 07001711T AT E432987 T1 ATE432987 T1 AT E432987T1
Authority
AT
Austria
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Application number
AT07001711T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Scot A Marsters
Mary A Napier
Robert M Pitti
William I Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE432987T1 publication Critical patent/ATE432987T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07001711T 1998-12-22 1999-12-02 Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums ATE432987T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US13023299P 1999-04-21 1999-04-21
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
ATE432987T1 true ATE432987T1 (de) 2009-06-15

Family

ID=27557838

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04007617T ATE353339T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
AT07001711T ATE432987T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04007617T ATE353339T1 (de) 1998-12-22 1999-12-02 Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums

Country Status (13)

Country Link
EP (1) EP1141284A2 (de)
JP (5) JP3993746B2 (de)
KR (1) KR100499600B1 (de)
AT (2) ATE353339T1 (de)
AU (1) AU768230B2 (de)
CA (1) CA2353799A1 (de)
DE (2) DE69940964D1 (de)
DK (1) DK1484338T3 (de)
ES (2) ES2327785T3 (de)
IL (3) IL143031A0 (de)
MX (1) MXPA01006330A (de)
PT (1) PT1484338E (de)
WO (1) WO2000037638A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
CA2309897A1 (en) 1997-11-22 1999-06-03 Hyseq, Inc. A novel egf motif protein obtained from a cdna library of fetal liver-spleen
EP1251139A3 (de) * 1998-04-08 2002-12-18 Genentech, Inc. Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
BR0007556A (pt) 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
JP2003505350A (ja) * 1999-07-20 2003-02-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
KR20020062652A (ko) * 1999-12-09 2002-07-26 상꾜 가부시키가이샤 고지혈증의 치료 또는 예방제의 시험방법
AU784349C (en) * 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2001085193A2 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
EP1859277A4 (de) 2005-02-17 2010-03-17 Biogen Idec Inc Behandlung neurologischer störungen
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2007117657A2 (en) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
EP2097455B1 (de) 2006-11-02 2014-10-22 Genentech, Inc. Humanisierte anti-faktor d-antikörper
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Also Published As

Publication number Publication date
EP1141284A2 (de) 2001-10-10
JP2005245451A (ja) 2005-09-15
KR20010084882A (ko) 2001-09-06
CA2353799A1 (en) 2000-06-29
JP2003529317A (ja) 2003-10-07
ES2327785T3 (es) 2009-11-03
ES2281704T3 (es) 2007-10-01
AU768230B2 (en) 2003-12-04
DK1484338T3 (da) 2007-06-11
ATE353339T1 (de) 2007-02-15
WO2000037638A3 (en) 2000-11-09
JP2007222180A (ja) 2007-09-06
IL186153A0 (en) 2008-01-20
JP2005237383A (ja) 2005-09-08
DE69935085T2 (de) 2007-08-23
AU1749900A (en) 2000-07-12
JP2007291116A (ja) 2007-11-08
JP3993746B2 (ja) 2007-10-17
PT1484338E (pt) 2007-05-31
IL186154A0 (en) 2008-01-20
MXPA01006330A (es) 2002-07-02
JP4037876B2 (ja) 2008-01-23
DE69935085D1 (de) 2007-03-22
IL143031A0 (en) 2002-04-21
DE69940964D1 (de) 2009-07-16
KR100499600B1 (ko) 2005-07-07
WO2000037638A2 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
ATE432987T1 (de) Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
ATE408419T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
ATE444971T1 (de) Zusammensetzungen und verfahren für die tumor- behandlung
DE69940681D1 (de) Zusammensetzung und Verfahren zur Diagnose von Tumoren
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP2075335A3 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
EP1870464A3 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
KR100515858B1 (en) PRO617 Polypeptides
WO2000007545A3 (en) Apoptosis proteins
KR100515857B1 (en) PRO792 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
KR100515856B1 (en) PRO618 Polypeptides
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties